Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004023320 | SCV002755179 | uncertain significance | not specified | 2019-09-28 | criteria provided, single submitter | clinical testing | The p.R310Q variant (also known as c.929G>A), located in coding exon 8 of the GARS gene, results from a G to A substitution at nucleotide position 929. The arginine at codon 310 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Antonellis Laboratory at Michigan, |
RCV000496771 | SCV000579487 | pathogenic | GARS-associated growth retardation and developmental delay | no assertion criteria provided | clinical testing | This variant is associated with a recessive, multi-system disorder described in PMID:28675565. |